Biotechnology company · UTHR

United Therapeutics
clinical trial
pipeline

Registry checked

Published

Treprostinil is linked to 3 distinct active studies: 1 recruiting, 1 active but not recruiting, 1 enrolling by invitation. Ralinepag is linked to 1 distinct active study: 1 enrolling by invitation.

Phase 3 study NCT03683186 in PAH and Pulmonary Hypertension lists estimated primary completion in December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

8active trials
as lead sponsor
  • Phase 10
  • Phase 22
  • Phase 33
  • Phase 41
  • Phase not recorded2

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

21 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000221
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals0000221 distinct

02 / Drugs & programmes

Explore the pipeline

2 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Treprostinil

orenitram · tyvaso · tyvasodpi · YUTREPIA

3
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 41
  • Phase not recorded0
Studied condition
Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease · Progressive Pulmonary Fibrosis
Next primary completion
Nov 2027 · estimated
Open drug

Ralinepag

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Cardiovascular Diseases · Connective Tissue Diseases · Familial Primary Pulmonary Hypertension
Next primary completion
Dec 2026 · estimated
Open drug

4 of 8 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

2 selected programmes · accepted investigational links cover 4 of 8 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

United Therapeutics trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
5 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Ralinepag

NCT03683186

Phase 3 · Enrolling by invitation

Trial source and qualifications

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

Start clipped at the display horizon.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 23 Sept 2019 · actual
    Primary completion: Dec 2026 · estimated
    Study completion: Dec 2026 · estimated

    2021202220232024202520262027202820292030
    Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
    Treprostinil

    NCT05943535

    Phase 3 · Recruiting

    Trial source and qualifications

    Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 30 Oct 2023 · actual
      Primary completion: Nov 2027 · estimated
      Study completion: Nov 2027 · estimated

      2021202220232024202520262027202820292030
      EXPAND
      Asset mapping not recorded

      NCT06878560

      Phase 2 · Recruiting

      Trial source and qualifications

      Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

      Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

      End clipped at the display horizon.

      4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      4 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 29 Oct 2025 · actual
        Primary completion: Oct 2028 · estimated
        Study completion: Oct 2075 · estimated

        2021202220232024202520262027202820292030
        EXTEND
        Asset mapping not recorded

        NCT07224763

        Phase 2 · Recruiting

        Trial source and qualifications

        Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

        Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        End clipped at the display horizon.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 1 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: Nov 2026 · estimated
          Primary completion: Nov 2029 · estimated
          Study completion: Nov 2076 · estimated

          2021202220232024202520262027202820292030
          TETON-OLE
          Treprostinil

          NCT04905693

          Phase 3 · Enrolling by invitation

          Trial source and qualifications

          Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

          2 candidate observations · 1 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          1 inspected observations omitted. At most three verified observations are shown, not full history.

          • pc date moved · Recorded 2026-07-29 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 06 Sept 2022 · actual
          Primary completion: Dec 2029 · estimated
          Study completion: Dec 2029 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          5 selected of 5 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          4

          active trials in Respiratory

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Respiratory4 trials
          • Renal & Urology2 trials
          • Unmapped2 trials
          • Healthy volunteers0 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies
          EL

          Eli Lilly

          Shared indexed programme context · 1 selected asset

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Enumerated controlled company group covers 89 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: United Therapeutics · Miromatrix Medical Inc.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          89 distinct registry candidates produced 89 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 89 unverified, 6 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          78 scoped records have indexed enrichment and 11 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T01:02:31.336Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 3b4fb7b351b384b5c1d92c7ec23843f172489b5c4258a0b9958d322d37d76d19.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 89 mapped lead-sponsored clinical studies across all statuses. 78 have indexed enrichment, 11 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.